Long-term result of the MRC AML10 trial

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 6, 2006, Pages 445-451

  Burnett, Alan K ^a,e   Wheatley, Keith ^b   Goldstone, Anthony H ^c   Stevens, Richard ^f   Hann, Ian ^d   Hills, Robert K ^b  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f NONE

Author keywords

Acute myeloid leukemia; Allograft; Autograft

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; ACUTE DISEASE; ALLOTRANSPLANTATION; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MYELOID LEUKEMIA; NEWBORN; PRESCHOOL CHILD; REMISSION; RISK FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33745775266     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia: results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood. 1997;89:2311-2318.
2. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69-79.
3. Burnett AK, Goldstone AH, Stevens R, et al. Randomised comparison of addition of autologous bone-marrow transplantation in intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700-708.
4. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 trial. Br J Haematol. 2002;118;385-400.
5. Bishop JF, Lowenthal PM, Joshua D, et al. Etoposide in acute non-lymphoblastic leukemia. Blood. 1990;75:27-32.
6. Gorin NC, Aegerter B, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood. 1990;75:1606-1614.
7. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML: 10 Trial. Blood. 1998;92:2322-2333.
8. Dicke KA, Zander A, Spitzer G, et al. Autologous bone marrow transplantation in relapsed adult acute leukaemia. Lancet. 1979;1:514-517.
9. Burnett AK, Tansey P, Watkins R, et al. Transplantation of unpurged autologous bone marrow in acute myeloid leukemia in first remission. Lancet. 1984;2:1068-1070.
10. Goldstone AH, Anderson CC, Linch DC, et al. Autologous bone marrow transplantation following high dose therapy for the treatment of adult patients with acute myeloid leukaemia. Br J Haematol. 1986;64:529-537.
11. Stewart P, Buckner CD, Bensinger WI, et al. Autologous marrow transplantation in patients with acute non-lymphocytic leukemia in first remission. Exp Hematol. 1985;13:267-272.
12. Lowenberg B, Verdonk LJ, Dekker AW, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol. 1990;8:287-294.
13. Burnett AK, Goldstone AH, Milligan DW. Daunorubicin versus mitoxantrone as induction for AML in younger adults given intensive chemotherapy: preliminary results of MRC AML12 Trial. Br J Haematol. 1999;105(suppl 1):67a.
14. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658-3665.
15. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) leukemia cooperative groups. N Engl J Med. 1995;332:217-223.
16. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90:2978-2986.
17. Cassileth PA, Harrington DP, Appelbaum F, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
18. Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. Br J Haematol. 1998;102:1344-1353.